Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow LEXICON PHARMACEUTICALS, INC.

Get SEC filing alerts via email and in your feed for LEXICON PHARMACEUTICALS, INC.

LXRX

LEXICON PHARMACEUTICALS, INC.

About LEXICON PHARMACEUTICALS, INC.

Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing small molecule drugs for serious conditions such as neuropathic pain, obesity, heart failure, hypertrophic cardiomyopathy, and type 1 diabetes. It leverages internal drug discovery and strategic alliances to identify novel targets, with key products including INPEFA (sotagliflozin). The company collaborates globally, outsources manufacturing, and operates in highly regulated markets to bring innovative therapies to patients.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from LEXICON PHARMACEUTICALS, INC.

1
1
LEXICON PHARMACEUTICALS, INC. Lexicon Pharmaceuticals Reports $21.1 Million Revenue and Improved Net Loss in Latest Quarter

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
LEXICON PHARMACEUTICALS, INC. Lexicon Pharmaceuticals Reports Revenue Growth to $49.8 Million, Net Loss Improves

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
LEXICON PHARMACEUTICALS, INC. Lexicon Pharmaceuticals Reports $14.2M Revenue in Q3 2025, Driven by Novo Nordisk Licensing Agreement

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
LEXICON PHARMACEUTICALS, INC. Lexicon Pharmaceuticals Reports $28.9M Revenue Surge in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
LEXICON PHARMACEUTICALS, INC. Lexicon Pharmaceuticals Reports 12% Revenue Growth and Improved Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
LEXICON PHARMACEUTICALS, INC. Lexicon Pharmaceuticals Reports $200.4 Million Net Loss and $31.1 Million Revenue for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
LEXICON PHARMACEUTICALS, INC. Lexicon Pharmaceuticals Reports Significant Revenue Growth, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments